Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity - Top-Institutions - MDSpire

Combination of Ixekizumab and Tirzepatide Results in Enhanced Disease Management Compared to Ixekizumab Monotherapy in Adults with Psoriatic Arthritis and Overweight or Obesity

  • By

  • Joseph F. Merola

  • Cynthia E. Kartman

  • Peter Fischer

  • Luna Sun

  • Anabela Cardoso

  • Mark C. Genovese

  • Alexis Ogdie

  • June 11, 2026

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Rheumatology

  • #2

    O'Donnell School of Public Health
    O'Donnell School of Public Health

    Dallas, Texas

    Key Differentiators

    • Public Health

  • #3

    Perelman School of Medicine, University of Pennsylvania
    Perelman School of Medicine, University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Medicine

  • #4

    American College of Physicians
    American College of Physicians

    Philadelphia, Pennsylvania

    Key Differentiators

    • Internal Medicine

  • #5

    CorEvitas Psoriasis Registry
    CorEvitas Psoriasis Registry

    N/A, N/A

    Key Differentiators

    • Registry

Original Source(s)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

  • by Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie

  • June 11, 2026

Related Content

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

A clinical care pathway for managing pregnancy in patients with inflammatory arthritis

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial